Ubisol‐Q halts the progression of parkinsonian neurodegeneration in rodent models of Parkinson's disease

Abstract

Coenzyme Q10 is a candidate for neuroprotection in Parkinson's disease (PD), in which both energy failure and oxidative stress are responsible for its progressive nature. The low therapeutic efficacy of CoQ10 in clinical trials of PD may be due to its insolubility in aqueous media, poor bioavailability and penetration into the brain. We have developed a technology to solubilize CoQ10 in water (Ubisol‐Q) in order to increase its therapeutic potential. Oral administration of Ubisol‐Q, containing PTSTM and CoQ10, elevated plasma and brain levels of both CoQ10 and vitamin E, in rats and mice. A prophylactic application of Ubisol‐Q (48 mg/kg/day or 6 mg/kg/day) in rodent models of PD (MPTP and paraquat) revealed a near complete protection of dopamine neurons. A therapeutic application of Ubisol‐Q, started immediately after the initiation of neuronal injury, protected dopamine neurons and preserved dopamine nerve terminals in both models of PD. Ubisol‐Q also resulted in a marked improvement in motor function of mice and rats performing on a beam walk test. The results of these pre‐clinical studies are highly encouraging and suggest that Ubisol‐Q, at lower doses than other CoQ10 products, has improved bioavailability and superior therapeutic efficacy and could be used as an adjuvant therapy in the management of PD. Ubisol‐Q is GRAS and will be tested clinically. Funding by MJFF and Zymes.